Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2351 to 2360 of 2706 total matches.
In Brief: Low-Dose Chlorthalidone (HemiClor) for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
(Edarbyclor) and atenolol (Tenoretic, and
generics).1,2
CHLORTHALIDONE — Chlorthalidone is more potent
than ...
The FDA has approved a 12.5-mg tablet formulation
of the thiazide-like diuretic chlorthalidone (HemiClor –
Ingenus) for treatment of hypertension. Chlorthalidone
has been available for years in 15-, 25-, and 50-mg
tablets (Thalitone, and generics) and in fixed-dose
combinations with azilsartan medoxomil (Edarbyclor)
and atenolol (Tenoretic, and generics).
Med Lett Drugs Ther. 2025 Jul 21;67(1733):118 doi:10.58347/tml.2025.1733e | Show Introduction Hide Introduction
In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026 (Issue 1751)
-related macular degeneration,
diabetic macular edema, and diabetic retinopathy.1
A CLINICAL STUDY ...
Eylea HD (Regeneron), which contains 8 mg of the
vascular endothelial growth factor (VEGF) inhibitor
aflibercept, has now been approved by the FDA for
intravitreal treatment of macular edema following
retinal vein occlusion (RVO). A 2-mg dose of aflibercept
(Eylea) was approved previously for this indication.
Eylea and Eylea HD are also approved for treatment of
neovascular (wet) age-related macular degeneration,
diabetic macular edema, and diabetic retinopathy.
Med Lett Drugs Ther. 2026 Mar 30;68(1751):56 doi:10.58347/tml.2026.1751b | Show Introduction Hide Introduction
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
have been reported,
particularly after >1 month of use
Hyperalgesia, worsening pain that cannot be overcome ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Drugs of Choice for Cancer
Treatment Guidelines from The Medical Letter • Mar 01, 2003 (Issue 7)
. (ISSN 1541-2784)
Vol. 1 (Issue 7) March 2003
Published by The Medical Letter, Inc.
1000 Main ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
The Viralizer For The Common Cold
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989 (Issue 784)
or omission. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
Recently, full-page advertisements have appeared in the New York Times and other newspapers promoting the Viralizer (Viral Response Systems, Greenwich, CT), a heated nebulizer-sprayer device marketed for treatment of colds, sore throats, allergy and sinusitis symptoms. The device is available without a prescription for about $30 to $40.
Desflurane - A New Volatile Anesthetic
The Medical Letter on Drugs and Therapeutics • Apr 30, 1993 (Issue 895)
. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http ...
Desflurane (Suprane - Anaquest), an inhalation anesthetic, has been approved by the US Food and Drug Administration for induction and maintenance of general anesthesia in adults and for maintenance of anesthesia in infants and children. Like isoflurane (Forane), the last volatile anesthetic to become available in the USA (Medical Letter, 23:112, 1981), the new agent is a halogenated methyl ethyl ether, differing from isoflurane in the substitution of a fluorine for a chlorine atom.
Pallidotomy for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Dec 06, 1996 (Issue 989)
. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Ablation of the globus pallidus, an old treatment for Parkinsons disease, is being tried again, using more refined stereotactic techniques, improved brain imaging and new methods for recording neuronal activity (CW Olanow, Ann Neurol, 40:341, September 1996).
Safety of Dronedarone (Multaq)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
for oral treatment
of paroxysmal or persistent (non-permanent) atrial
fibrillation or atrial flutter.1 ...
Dronedarone (Multaq – Sanofi), an analog of amiodarone,
was approved by the FDA in 2009 for oral treatment
of paroxysmal or persistent (non-permanent) atrial
fibrillation or atrial flutter. Amiodarone (Cordarone, and
others) is more effective for this indication, but its use is
often limited by its adverse effects, including thyroid and
pulmonary toxicity.
Prosthetic Heart Valves
The Medical Letter on Drugs and Therapeutics • Aug 20, 2012 (Issue 1397)
than those in the aortic position.1
Mechanical valves are preferred for younger patients
( ...
Prosthetic heart valves have been used effectively in
patients with mitral and aortic valvular heart disease
for more than 50 years, but no replacement valve
developed to date is suitable for all types of patients.
In Brief: Anktiva for Bladder Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
) are
also approved for the same indication.1
underwent transurethral resection of the tumor
before ...
Nogapendekin alfa inbakicept-pmln (Anktiva –
ImmunityBio), a first-in-class interleukin-15 (IL15)
receptor agonist, has been approved by the FDA for
use with Bacillus Calmette-Guérin (BCG) for treatment
of patients with BCG-unresponsive nonmuscle
invasive bladder cancer (NMIBC) with carcinoma in
situ with or without papillary tumors. Such patients
generally undergo bladder tumor resection, followed
by intravesical BCG treatment, but treatment failure
and cancer recurrence are common. The adenoviral
vector-based intravesical gene therapy nadofaragene
firadenovec-vncg (Adstiladrin)...
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-6 doi:10.58347/tml.2024.1705e | Show Introduction Hide Introduction
